Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC)

被引：0

作者：

Van Cutsem, E. ^{[1
,2
]}

Ciardiello, F. ^{[3
]}

Seitz, J. -F. ^{[4
]}

Hofheinz, R. D. ^{[5
]}

Verma, U. ^{[6
]}

Garcia-Carbonero, R. ^{[7
]}

Grothey, A. ^{[8
]}

Miriyala, A. ^{[9
]}

Kalmus, J. ^{[10
]}

Shapiro, J. ^{[11
]}

Falcone, A. ^{[12
]}

Zaniboni, A. ^{[13
]}

机构：

[1] Univ Hosp Leuven, Digest Oncol, Leuven, Belgium

[2] Katholieke Univ Leuven, Leuven, Belgium

[3] Univ Naples 2, Dept Expt & Clin Med & Surg, Naples, Italy

[4] Aix Marseille Univ, Assistance Publ Hop Marseille, Dept Digest Oncol, Marseille, France

[5] Heidelberg Univ, Univ Med Mannheim, Interdisziplinaren Tumorzentrum, Mannheim, Germany

[6] Univ Texas SW Med Ctr Dallas, Div Hematol & Oncol, Dallas, TX 75390 USA

[7] Hosp Univ Virgen del Rocio, Dept Med Oncol, Seville, Spain

[8] Mayo Clin, Dept Oncol, Rochester, NY USA

[9] Bayer Pharma AG, Global Pharmacovigilance & Risk Management, Berlin, Germany

[10] Bayer Pharma AG, Global Clin Dev Oncol Ophthalmol & Neurol, Berlin, Germany

[11] Bayer HealthCare Pharmaceut, Clin Stat, Whippany, NJ USA

[12] Univ Pisa, Dept Med Oncol, Pisa, Italy

[13] Fdn Poliambulanza, Dept Oncol, Brescia, Italy

来源：

ANNALS OF ONCOLOGY | 2015年 / 26卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

140O

引用

页码：42 / 42

页数：1

共 50 条

[1] Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study
Ciardiello, F.
Falcone, A.
Cascinu, S.
Sobrero, A.
Boni, C.
Barone, C.
Luppi, G.
Maiello, E.
Siena, S.
Zagonel, V.
Carteni, G.
Di Constanzo, F.
Di Bartolomeo, M.
Santoro, A.
Russo, A.
Moscovici, M.
Van Cutsem, E.
Zaniboni, A.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S380 - S381
[2] Analysis of patients ≥75 years in the open-label phase 3b CONSIGN trial of regorafenib in previously treated metastatic colorectal cancer (mCRC)
Van Cutsem, E.
Ciardiello, F.
Ychou, M.
Seitz, J. -F.
Hofheinz, R.
Arriaga, Y.
Garcia-Carbonero, R.
Grothey, A.
Miriyala, A.
Kalmus, J.
Kappeler, C.
Falcone, A.
Zaniboni, A.
ANNALS OF ONCOLOGY, 2016, 27 : 106 - 106
[3] Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial
Kasper, S.
van Cutsem, E.
Ciardello, F.
Ychou, M.
Seitz, J. -F
Hofheinz, R. -D
Arriaga, Y. E.
Verma, U.
Garcia-Carbonero, R.
Grothey, A.
Miriyala, A.
Kalmus, J.
Kappeler, C.
Falcone, A.
Zaniboni, A.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 94 - 95
[4] Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial
Ciardiello, F.
Salvatore, L.
Cascinu, S.
Sobrero, A.
Banzi, C.
Barone, C.
Spallanzani, A.
Latiano, T. P.
Siena, S.
Bergamo, F.
Carteni, G.
Di Costanzo, F.
Di Bartolomeo, M.
Santoro, A.
Russo, A.
Russo, A.
Moscovici, M.
Van Cutsem, E.
Grothey, A.
Zaniboni, A.
ANNALS OF ONCOLOGY, 2016, 27
[5] Regorafenib for previously treated metastatic colorectal cancer (mCRC): results from 683 Italian patients treated in the open-label phase IIIB CONSIGN study
Ciardiello, F.
Salvatore, L.
Cascinu, S.
Sobrero, A.
Banzi, M.
Barone, C.
Spallanzani, A.
Latiano, T. L.
Amatu, A.
Zagonel, V.
Biglietto, M.
Di Costanzo, F.
Di Bartolomeo, M.
Santoro, A.
Russo, A.
Moscovici, M.
Van Cutsem, E.
Zaniboni, A.
ANNALS OF ONCOLOGY, 2015, 26 : 37 - 37
[6] CONSIGN: An open-label phase 3B study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy
Van Cutsem, E.
Ciardiello, F.
Seitz, J. F.
Hofheinz, R. D.
Verma, U.
Garcia-Carbonero, R.
Grothey, A.
Miriyala, A.
Kalmus, J.
Shapiro, J.
Falcone, A.
Zaniboni, A.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S378 - S379
[7] Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase IIIb CONSIGN trial.
Van Cutsem, Eric
Ciardiello, Fortunato
Ychou, Marc
Seitz, Jean Francois
Hofheinz, Ralf
Arriaga, Yull Edwin
Verma, Udit
Garcia-Carbonero, Rocio
Grothey, Axel
Miriyala, Ashok
Kalmus, Joachim
Kappeler, Christian
Falcone, Alfredo
Zaniboni, Alberto
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[8] Regorafenib for previously treated metastatic colorectal cancer (mCRC): A subgroup analysis of 364 patients in the USA treated in the international, open-label phase IIIb CONSIGN study.
Verma, Udit
Arriaga, Yull Edwin
Lenz, Heinz-Josef
Henderson, Charles A.
Fuloria, Jyotsna
Cartwright, Thomas H.
Khojasteh, Ali
Stella, Philip J.
Saltzman, Marc
Cohn, Allen Lee
Philip, Philip Agop
Kappeler, Christian
Kalmus, Joachim
Grothey, Axel
Van Cutsem, Eric
Hochster, Howard S.
Arena, Francis P.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[9] CONSIGN - an open-label phase-3B-study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy
Hofheinz, R. -D
Glardello, F.
Seitz, J-F
Verma, U.
Garcia-Carbonero, R.
Grothey, A.
Miriyala, A.
Kalmus, J.
Shapiro, J.
Falcone, A.
Zanibonl, A.
van Cutsem, E.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 10 - 10
[10] Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
Van Cutsem, Eric
Martinelli, Erika
Cascinu, Stefano
Sobrero, Alberto
Banzi, Maria
Seitz, Jean-Francois
Barone, Carlo
Ychou, Marc
Peeters, Marc
Brenner, Baruch
Hofheinz, Ralf Dieter
Maiello, Evaristo
Andre, Thierry
Spallanzani, Andrea
Garcia-Carbonero, Rocio
Arriaga, Yull E.
Verma, Udit
Grothey, Axel
Kappeler, Christian
Miriyala, Ashok
Kalmus, Joachim
Falcone, Alfredo
Zaniboni, Alberto
ONCOLOGIST, 2019, 24 (02): : 185 - 192

← 1 2 3 4 5 →